• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Direct oral anticoagulants more effective in patients with valvular atrial fibrillation

byThomas SuandHarsh Shah
April 12, 2021
in Cardiology, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients who received a direct oral anticoagulant had a lower risk of thromboembolic events and major bleeds compared to patients who received warfarin.

2. The between-group differences were consistent across all prespecified clinically relevant subgroups.

Evidence Rating Level: 2 (Good)

Study Rundown: It is recommended for patients with atrial fibrillation to receive prophylactic anticoagulant therapy to guard against an increased risk of stroke and other thromboembolic events. Numerous studies have demonstrated direct oral anticoagulants (DOACs) have greater antithrombotic effects and lower bleeding risk compared to warfarin in patients with nonvalvular atrial fibrillation. However, little direct evidence exists to confirm the efficacy and safety of DOACs in patients with both atrial fibrillation and valvular heart disease. In this new-user study involving over 55,000 patients with valvular atrial fibrillation, those who received a DOAC had a significantly lower risk for both major bleeding (gastrointestinal or intracranial) and the composite of ischemic stroke or systemic embolism (SE). These findings were robust in sensitivity analyses, consistent across demographic and clinical variables, and largely independent of the specific DOAC used (apixaban, rivaroxaban, dabigatran, or edoxaban). The study was limited by the lack of data regarding the concomitant use of over-the-counter drugs and the severity of valvular disease. Overall, these results contribute to the pool of observational evidence that supports the consideration of DOACs as a treatment option for patients with valvular atrial fibrillation.

Click here to read the study in Annals of Internal Medicine

Relevant Reading: Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)

In-Depth [retrospective cohort]: This study identified 46,276 new users of DOACs and 34,967 new users of warfarin. Patients who were 18 years or older and had a valvular heart disease diagnosis were included in the study. The study exclusion criteria included end-stage renal failure, history of stroke or systemic embolism, and heart valve replacement. The primary effectiveness outcome was a composite of ischemic stroke or SE, while the primary safety outcome was a composite of intracranial or gastrointestinal bleeding. At the end of the study, 787 DOAC users had stroke or SE after a median follow-up of 134 days (3.9 events per 100 person-years) compared to 1,211 warfarin users after a median follow-up of 124 days (6.0 events per 100 person-years). This corresponded to a hazard ratio of 0.64 (95% confidence interval [CI], 0.59 to 0.70) and an absolute reduction in the probability of stroke or SE with DOACs compared with warfarin of 0.015 within 6 months and 0.026 within 1 year. For the risk of major bleeding, 1,465 DOAC users had an event (7.1 events per 100 person-years) compared to 2,155 warfarin users (10.6 events per 100 person-years). This corresponded to a hazard ratio of 0.67 (95% CI, 0.63 to 0.72) and an absolute reduction in the probability of major bleeding of 0.019 within 6 months and 0.035 within 1 year. These differences persisted across subgroups defined by age, sex, cancer, abnormal coagulation, and type of valvular heart disease. Overall, the study determined DOAC lowered the risk of ischemic stroke SE in patients with valvular atrial fibrillation.

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Endovascular therapy for large ischemic strokes provides better functional outcomes

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

Image: PD

 ©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atrial fibrillationdirect oral anticoagulant (DOAC)ischemic strokevalvular disease
Previous Post

Sutimlimab improved hemoglobin and patient symptoms in cold agglutinin disease

Next Post

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Patient Basics: Stroke Overview
Emergency

Endovascular therapy for large ischemic strokes provides better functional outcomes

April 22, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Combined MRI and NIH stroke scores may predict stroke prognosis
Emergency

Large vessel occlusion stroke is associated with poor prognosis in children

March 29, 2022
Next Post
Pediatric renal and thyroid cancer rates increase

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

Time-limited trials may decrease the length of stay of critically ill patients in the intensive care unit

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.